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Abstract We have constructed two fusion proteins, D A B 3 8 9 -
raIL-3 and DAB389-(Gly4Ser)2-mIL-3, in which the receptor-
binding domain of diphtheria toxin is replaced by mouse 
interleukin-3 (IL-3). Cytotoxic activity of the fusion toxins was 
observed on three out of six cell lines assayed. This toxicity was 
mediated through binding to the IL-3 receptor as it was inhibited 
in a dose-dependent manner with murine IL-3 or anti-IL-3 
neutralizing antibodies. DAB389-(Gly4Ser)2-mIL-3 was up to 
5 times more toxic than DAB3 Sg-mIL-3, depending on the cell 
line (0 .8X10 1 0 M < I C 5 0 < 3 X 1 0
 1 0 M). These proteins can 
be used for the detection of IL-3 receptors on mouse cells and 
should allow for the selective elimination of IL-3 receptor-
positive pluripotent hematopoietic stem cells prior to bone 
marrow transplantation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Interleukin-3 (IL-3) can stimulate the proliferation and dif-
ferentiation of pluripotent hematopoietic stem cells as well as 
various lineage-committed progenitors [1]. The use of a cyto-
toxic agent highly specific for cells expressing the IL-3 recep-
tor may have therapeutic potential in the removal of these 
cells prior to bone marrow grafting. Such treatment could 
prevent the side effects of conventional bone marrow deple-
tion therapies, including toxicity for more mature hemato-
poietic cells and for fast dividing cells from other tissues. 
In the past 15 years, many efforts have been made to target 
plant or bacterial toxins to specific cell populations [2]. Ge-
netic fusion of the diphtheria toxin catalytic and translocation 
domains to various polypeptide hormones led to highly effi-
cient and specific targeted toxins [3] safe enough to be used in 
humans as anti- tumor [4,5] or immunosupressive therapeutics 
[6-8]. 
We describe the construction of the fusion toxins D A B 3 8 9 -
mIL-3 and DAB3 8 9-(Gly4Ser)2-mIL-3 aimed at killing cells 
expressing murine IL-3 (mIL-3) receptors. We demonstrate 
that the cytotoxic activity of these proteins is dependent on 
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binding to the mIL-3 receptor, and that insertion of the 
(Gly4Ser)2 spacer between the diphtheria toxin translocation 
domain and mIL-3 enhances toxicity up to 5-fold. 
2. Materials and methods 
2.1. Bacterial strains 
Escherichia coli strain JM101 was used for plasmid propagation and 
cloning and strain BL21(DE3) (Novagen, Madison, WI) was used as 
the host for fusion toxins production. 
2.2. Construction of vectors pCGmIL-3 and pCCmIL-3 
The pETlld derived parental plasmid pETJV127 [9] encoding the 
diphtheria toxin-IL-2 fusion DAB3gg-IL-2 was digested with Ncol to 
introduce a DNA fragment made by hybridization of the following 
oligonucleotides: 5' -CATGGGTCATCACCATCACCATCACGAT-
GACGATGACAAAGG-3' and 5'-CATGCCTTTGTCATCGTCAT-
CGTGATGGTGATGGTGATGACC-3'. As a result, the N-terminal 
methionine of the encoded DAB389-IL-2 protein is preceded by the 
following sequence: Met-Gly-His-His-His-His-His-His-Asp-Asp-
Asp-Asp-Lys-Gly. The resulting plasmid pCGl was digested with 
SphI and Hindlll to remove the IL-2 coding region at the 3'-end of 
the structural gene for DAB389-IL-2. The coding sequence for mIL-3 
was PCR-amplified from the mIL-3 cDNA (R&D Systems, Abingdon, 
UK) using primers designed to introduce a SpM and a HindlU re-
striction site at the 5'- and 3'-ends of the fragment, respectively: 5'-
GGAGGCGGGCGCATGCTGATACCCACCGTTTAACC-3' and 
5'-GGCCGCGAGCAAGCTTTCATTAACATTCCACGGTTCC-3'. 
After digestion with SphI and HindUl, the mIL-3-amplified sequence 
was ligated in plasmid pCGl to give plasmid pCGmIL-3. Plasmid 
pCCmIL-3 was derived from pCGmIL-3 by insertion at its SphI site 
of a DNA fragment made by hybridization of the following oligonu-
cleotides: 5'-GTGGCGGTGGATCCGGCGGTGGCGGTTCGCA-
TG-3' and 5'-CGAACCGCCACCGCCGGATCCACCGCCACCA-
TG-3'. As a result, the sequence (GlyiSer^ separates the diphtheria 
toxin translocation domain and mIL-3 in the encoded protein. All 
DNA insertions were checked by DNA sequence analysis. 
2.3. Expression and extraction of the fusion toxins 
Protein expression was under control of the T7 RNA polymerase 
promoter in E. coli BL21(DE3). Cultures were grown at 30°C in TSB 
medium (17 g/1 Tryptone, 3 g/1 Soytone, 5 g/1 yeast extract (Difco, 
Detroit, MI), 2.5 g/1 K 2HP0 4 , 5 g/1 NaCl) supplemented with 5 g/1 
glucose and 0.2 mg/1 ampicillin. Two liters of medium were inoculated 
with an overnight culture of bacterial cells carrying plasmid pCGmlL-
3 or pCCmIL-3 at a 1:50 dilution. When the absorbency at 600 nm 
reached 0.7, expression of the recombinant protein was induced by the 
addition of 0.5 mM isopropyl-fi-D-thiogalactopyranoside. After 2 h, 
cells were harvested by centrifugation and resuspended in 20 ml of 50 
mM Tris-HCl, pH 8, 10 mM EDTA, 8% sucrose (w/v), 5% Triton X-
100 (v/v) supplemented with 0.1 ml of 0.1 M PMSF (Sigma, St. Louis, 
MO) in ethanol and 1 ml of a 10 mg/ml solution of lysozyme (Sigma). 
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After 1 h incubation on ice, the cells were lysed by sonication for 5 min 
(power setting: 50%; pulse: 1 s; rest: 1 s). The preparation was 
centrifuged at 14000Xg for 30 min at 4°C and the supernatant fluid, 
corresponding to the soluble cytoplasmic fraction, was dialyzed twice 
at room temperature against 8 M urea, 0.1 M sodium phosphate, 10 
mM Tris-HCl, pH 8, supplemented with 10 mM 2-mercaptoethanol. 
2.4. Purification and refolding of the fusion toxins 
The recombinant proteins were first purified by immobilized metal 
ion (Ni2+) affinity chromatography (IMAC). Four milliliters of Che-
lating Sepharose Fast Flow (Pharmacia Biotech, Uppsala, Sweden) 
was charged with Ni2+ in a column according to the manufacturer's 
instructions and equilibrated with the urea buffer used precedently. 
The cytoplasmic extract containing the fusion toxin was allowed to 
pass twice through the column at room temperature. The column was 
washed with 20 ml of urea buffer, and then with 10 ml of refolding 
buffer (50 mM Tris-HCl, pH 8, 50 mM NaCl, 5 mM reduced gluta-
thione, 1 mM oxidized glutathione). The flow of refolding buffer was 
stopped before complete passage, and the column was allowed to rest 
overnight at 4°C. After washing with 10 ml of 50 mM Tris-HCl, pH 8, 
50 mM NaCl, proteins were eluted in 10 ml of 50 mM Tris-HCl, pH 
8, 50 mM NaCl, 0.5 M imidazole. The protein sample was concen-
trated and dialyzed against 20 mM Tris-HCl, pH 7.4, 150 mM NaCl. 
Further purification was performed by anti-mIL-3 antibodies (R&D 
Systems) affinity chromatography. IMAC purified fusion toxin was 
bound to the column in 27 mM KH 2P0 4 , 46 mM NaOH, 10 mM 
EDTA, 0.75 M NaCl, 0.1% Tween 20, pH 8, and after washing in the 
same buffer, elution was performed in 0.1 M Na2CC>3, 0.5 M NaCl, 
0.1% Tween 20, at pH 11.3. The eluted sample was neutralized with 
1:10 volume of 2 M Tris-HCl, pH 6.8, and concentrated and dialyzed 
against 20 mM Tris-HCl, pH 7.4, 150 mM NaCl. 
2.5. SDS-polyacrylamide gel electrophoresis and Western blot analysis 
Protein containing samples were analyzed by 10% SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) according to conventional 
procedures, using a mini protean II apparatus (Bio-Rad, Ivry sur 
Seine, France). Proteins on the gels were either stained with Coomas-
sie blue or detected by conventional Western technique using the 
following primary and secondary antibodies: horse anti-diphtheria 
toxin (Merieux, Marcy-FEtoile, France) or goat anti-mIL-3 (R&D 
Systems), then rabbit anti-horse IgGs-peroxidase conjugate or rabbit 
anti-goat IgGs-peroxydase conjugate (Immunotech, Marseille, 
France). 
2.6. Cell cultures 
All cell culture media were supplemented with 10% fetal calf serum 
(Biological Industries, Kibbutz Beit Haemek, Israel) and 2 mM glu-
tamine. 
The Ba/F3 cell line transfected with the rabbit mammary prolactin 
(Prl) receptor cDNA [10] was the kind gift of Dr. Isabelle Dusanter-
Fourt, Institut Cochin de Genetique Moleculaire, Hopital Cochin, 
Paris, France. These cells were cultured in RPMI-1640 medium sup-
plemented with 0.5 nM (10 ng/ml) ovine Prl (NIDDK, Baltimore, 
MD). The FDC-P1 cell line transfected with the murine erythropoie-
tin (Epo) receptor cDNA [11] was the kind gift of Dr. Patrick 
Mayeux, Institut Cochin de Genetique Moleculaire. These cells were 
cultured in oc-MEM supplemented with 2 U/ml Epo. The HUT 102/ 
6TG cell line was cultured in RPMI-1640 medium. The cell lines 
P388D1, A20 and VERO were cultured in D-MEM. 
2.7. Cytotoxicity assays 
Cells were seeded at a density of 5X104 cells per well into 96-well 
MultiScreen-DV filtration plates (Millipore). The cells were exposed 
to various concentrations of the fusion toxins with or without re-
combinant mIL-3 or anti-mIL-3 antibodies in a final volume of 0.2 
ml culture medium supplemented with 0.5 g/1 gentamycin sulfate (Bio-
logical Industries). After incubation for 18 h at 37CC in a 6% CO2 
atmosphere, the medium was removed by aspiration on a Millipore 
MultiScreen device and replaced with 0.2 ml of leucine-free medium 
containing 1 u.Ci/ml [14C]leucine (292 mCi/mmol) (Isotopchim, Gana-
gobie-Peyruis, France), 2 mM glutamine and 0.5 g/1 gentamycine sul-
fate. After incubation for 3 h at 37°C in a 6% C0 2 atmosphere, the 
medium was removed by aspiration, the cells were lysed by the addi-
tion of 50 ill per well of 0.4 M KOH, and proteins were precipitated 
by the addition of 200 ul of 10% trichloroacetic acid. Insoluble ma-
terial was collected on a glass-fiber filter using a TOMTEC Harvester 
96 and radioactivity was counted in a 1450 MicroBeta liquid scintil-
lation counter (Wallac, Turku, Finland). 
3. Results 
3.1. Design, expression and purification of two diphtheria 
toxin-related mIL-3 fusion proteins 
The expression plasmid pCGmIL-3 encoding the diphtheria 
toxin-related mIL-3 fusion protein DAB389-mIL-3 was de-
rived from plasmid pETJV127 [9] encoding DAB389-IL-2, a 
diphtheria toxin-related IL-2 fusion protein [12] as described 
in Section 2. The N-terminus of DAB 3 8 9 -mIL-3 ( M e t - G l y -
H i s - H i s - H i s - H i s - H i s - H i s - A s p - A s p - A s p - A s p - L y s - G l y - M e -
t) which precedes the first glycine of mature diphtheria toxin, 
displays a six histidine tag for I M A C purification. This tag is 
followed by an enterokinase proteolytic cleavage site, for re-
moval if needed. The catalytic and translocation domains of 
diphtheria toxin are then fused to the N-terminus of mIL-3. 
In mice, two N-terminal variants of native mIL-3, containing 
either 140 or 134 amino acid residues, have been described. It 
is believed that the shorter form arises from secondary pro-
teolytic cleavage. Nevertheless, both forms have comparable 
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Fig. 1. SDS-PAGE analysis of purified DAB389-mIL-3 (top) and 
DAB389-(Gly4Ser)2-mIL-3 (bottom) under reducing or non-reducing 
conditions (2ME: p-mercaptoethanol) by Coomassie blue staining 
or Western detection using anti-mIL-3 antibodies or anti-diphtheria 
toxin antibodies. 
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activities in vitro [13]. In order to avoid the risk of proteolytic 
cleavage in vivo, we chose to link the shortest of these var-
iants to the C-terminus of the diphtheria toxin translocation 
domain. As a result, the sequence at the junction is -His-Lys-
Thr-His-Ala-Asp-Thr-His-. The first threonine corresponds 
to Thr387 of diphtheria toxin; the amino acid residues in bold 
characters correspond to the Sphl cloning site, and the as-
partic acid is the first amino acid residue of the shorter 
form of mIL-3. (Note: amino acid numbers correspond to 
that of the DABsgg-hormone fusion family and are therefore 
+1 with respect to mature diphtheria toxin.) 
Kiyokawa et al. [14] described that insertion of a peptidic 
spacer of at least 10 amino acid residues between the diph-
theria toxin part and the IL-2 part of the fusion toxin 
DAB38g-IL-2 enhanced its toxicity to IL-2-receptor-bearing 
cells 5-fold, due to increased accessibility of the hormone 
for its receptor. We thus derived plasmid pCCmIL-3 from 
pCGmIL-3 in order to insert the flexible and hydrophilic se-
quence (Gly4Ser)2 at the junction of the diphtheria toxin and 
the mIL-3 sequence of DAB389-mIL-3, leading to the mole-
cule DAB38g-(Gly4Ser)2-mIL-3. As a result, the sequence at 
the junction is -His-Lys-Thr-His Ala-Gly-Gly-Gly-Gly-
Ser-Gly-Gly-Gly-Gly-Ser-His-Ala-Asp-Thr-His- both 
His-Ala sequences corresponding to the doubling of the 
Sphl restriction sequence due to the oligonucleotide insertion, 
although a single nucleotide substitution alters the left-most 
site. 
DAB389-mIL-3 and DAB389-(Gly4Ser)2-mIL-3 were ex-
pressed under control of the T7 RNA polymerase promoter 
in E. coli BL21(DE3) and were found mainly in the soluble 
fraction of the cytoplasm. The proteins were purified under 
denaturing and reducing conditions on a Ni2+ IMAC column 
and refolded while still immobilized on the solid phase of the 
column, as described in Section 2. This refolding procedure 
avoids the handling of large volumes of highly diluted protein 
needed in case of liquid-phase refolding. DAB38g mIL-3 and 
DAB389-(Gly4Ser)2-mIL-3 were further purified by affinity 
chromatography using polyclonal anti-mIL-3 antibodies. 
Fig. 1 shows the detection of the fusion proteins after SDS-
PAGE of the purified samples, followed by Western blotting. 
The proteins reacted with both anti-diphtheria toxin and anti-
mIL-3 antibodies and have an electrophoretic mobility con-
sistent with the expected molecular mass of 59000 Daltons 
deduced from the amino acid sequence. Under reducing con-
ditions, both fusion toxins appear as two bands of slightly 
lower mobility than the band detected in non-reducing con-
ditions. We suggest that this pattern corresponds to the re-
duction of either one or both of the disulfide bonds present in 
the refolded fusion protein. One bond is expected to link the 
C-terminal part of the diphtheria toxin catalytic domain to 
the N-terminus of the translocation domain. Another bond is 
expected in mIL-3. 
Coomassie blue staining of the fusion proteins following 
SDS-PAGE shows that they are purified to about 80-90% 
homogeneity (Fig. 1). 
3.2. DABisg-mIL-3 is cytotoxic and cytotoxicity is targeted to 
the mIL-3 receptor 
The toxicity of DAB38g-mIL-3 was assayed on the bone 
marrow-derived murine pro-B lymphoid Ba/F3 cell line trans-
fected with the rabbit mammary Prl receptor cDNA [10]. Ba/ 
F3 cells express the mIL-3 receptor. They are dependent on 
either mIL-3 or Epo for propagation. However, the expression 
of a Prl receptor in these cells enables propagation in the 
absence of mIL-3, provided Prl is present [10], without the 
loss of mIL-3 receptor expression on the cell surface. Fig. 2 
shows that DAB38g-mIL-3 inhibited protein synthesis in Prl 
receptor-positive Ba/F3 cells in a dose-dependent manner, 
with an IC50 of 1 X 10~10 M. On the contrary, protein syn-
thesis of the IL-2 receptor-positive human cutaneous T-cell 
lymphoma cell line HUT 102/6TG was not significantly af-
fected after overnight incubation with 10~8 M DAB38g-mIL-3 
(Fig. 2A), although this cell line is highly sensitive to the IL-2 
receptor-targeted diphtheria toxin derivative DAB38g-IL-2 
[12]. 
DAB38g-mIL-3 cytotoxicity assays were repeated on Prl 
receptor-positive Ba/F3 cells in the presence of varying con-
centrations of recombinant mIL-3 (Fig. 2B). The cytotoxic 
effect of DAB38g-mIL-3 decreased by about 100-fold in the 
presence of an mIL-3 concentration of 10~9 M and about 10-
fold in the presence of an mIL-3 concentration of 10 -10 M. 
The cytotoxic effect of DAB38g-mIL-3 at a concentration of 
10 - 8 M was totally abolished in the presence of the same 
concentration of mIL-3 (10~8 M). 
Inhibition of cytotoxicity was also found in a dose-depend-
ent manner in the presence of dilutions of purified anti-mIL-3 
polyclonal antibodies (Fig. 2C). 
Taken together, these results demonstrate that the cytotoxic 
Table 1 
Cytotoxic activity of DAB389-mIL-3 and DAB389-(Gly4Ser)2-mIL-3 
Cell line 
Ba/F3-rPrl 
FDC-Pl-rEpo 
P388D1 
A20 
HUT102/6TG 
VERO 
Toxin IC50X10" 
(Gly4Ser)2 
1 
10 
15 
> 100 
> 100 
>100 
-10 M 
+ 
0.8 
2 
3 
> 100 
>100 
> 100 
(Gly4Ser)2 
-
+ 10-9 M mIL-3 
> 100 
>100 
>100 
> 100 
> 100 
> 100 
+ 
10 
80 
100 
> 100 
> 100 
>100 
(Gly4Ser)2 
-
+ 1 |ig/ml 
> 100 
> 100 
>100 
> 100 
>100 
> 100 
+ 
anti-mIL-3 
> 100 
>100 
>100 
> 100 
> 100 
> 100 
IC50 measured from cytotoxicity assays on various cell lines following exposure to DAB38g-mIL-3 or DAB389-(Gly4Ser)2-mIL-3 (— or + (Gly4Ser)2 
linker), in the absence or presence of mIL-3 or anti-mIL-3 antibodies as competitors. Values > 100 indicate that at the highest toxin concentration 
of 10~8 M, toxicity if any was lower than 50%. Variation between rephcates was lower than 20%. Maximum radioactivity incorporation ranged 
from 10000 to 40000 cpm depending on the cell line. 
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Fig. 2. Cytotoxicity assays following exposure to DAB389-mIL-3. 
A: Toxicity on Prl receptor-expressing Ba/F3 cells or HUT 102/ 
6TG cells. B: Toxicity on Prl receptor-expressing Ba/F3 cells in the 
absence or presence of various concentrations of recombinant mlL-
3. C: Toxicity on Prl receptor-expressing Ba/F3 cells in the absence 
or presence of various dilutions of anti-mIL-3 antibodies made from 
a 1 mg/ml solution. Measures were done in quadruplicates except in 
the presence of recombinant mIL-3 (B) in which case they were 
done in duplicate. Variation between replicates was lower than 20%. 
Maximum radioactivity incorporation reached about 35-40000 cpm. 
effect of the diphtheria toxin-related fusion protein DAB38g 
mIL-3 is mediated through binding to the mIL-3 receptor and 
that it is not toxic to a cell line devoid of that receptor. 
3.3. Comparison of the cytotoxic effects of DAB^Q-mIL-3 and 
DAB389-(GtyiSer)2-mIL-3 on various cell lines 
The toxicity of both DAB38g-mIL-3 and DAB38g 
(Gly4Ser)2-mIL-3 was assayed on six cell lines including the 
Prl receptor-positive Ba/F3 cells and the HUT102/6TG cells. 
The four other cell lines were the following: (1) the murine 
myelomonocytic leukemia cell line FDC-P1 transfected with 
the murine erythropoietin (Epo) receptor cDNA [11]. FDC-P1 
cells express the mIL-3 receptor and are dependent on mIL-3 
for propagation. However, the expression of the Epo receptor 
enables propagation in the absence of mIL-3, provided Epo is 
present [11]; (2) the murine macrophage-like cell line P388D1 
which was shown to respond to mIL-3 by secreting IL-1 [15]; 
(3) the African green monkey kidney cell line VERO, highly 
sensitive to native diphtheria toxin, but necessarily deprived of 
mIL-3 receptors; and (4) the murine B cell lymphoma cell line 
A20, for which the mIL-3 receptor expression status is un-
known to our knowledge. 
Each assay was performed with varying concentrations of 
toxins, in the absence or presence of 10~9 M mIL-3 or 1 |0.g/ml 
purified anti-mIL-3 antibodies. The results are summarized in 
Table 1. 
Both toxins inhibit protein synthesis in the three cell lines 
known to express mIL-3 receptors but not in cells devoid of 
that receptor. Interestingly, DAB389-(Gly4Ser)2-mIL-3 was 
found 5 times more toxic on two cell lines and slightly more 
toxic on a third one. In all cases, cytotoxicity could be inhib-
ited with either mIL-3 or anti-mIL-3 antibodies. 
4. Discussion 
We have shown that both fusion toxins DAB38g-mIL-3 and 
DAB389-(Gly4Ser)2-mIL-3 were cytotoxic to cells expressing 
the mIL-3 receptor, and that cytotoxicity was mediated 
through binding to that receptor. However, efficiency of tox-
icity varies depending on the targeted cell line. Several explan-
ations could account for this observation: the number of re-
ceptors on the cell surface, their affinity, or their rate of 
internalization, as it was shown that both diphtheria toxin 
[16,17] and the diphtheria toxin-related fusion toxins [18-21] 
need to be internalized into the cell by receptor-mediated en-
docytosis in order to exert their toxic action. 
While preparing this manuscript, we were aware of a work 
describing a diphtheria toxin-mIL-3 fusion, DT-3go-mIL-3 
[22], similar to DAB389-mIL-3. Unfortunately, one cannot 
compare the values of IC50 found in both studies, due to 
important differences in the cytotoxicity assay conditions. 
However, DAB38g-(Gly4Ser)2-mIL-3 was found 5-fold more 
toxic than DAB38g-mIL-3 on two of the three cell lines as-
sayed, while mIL-3 at a concentration of 10 - 9 M was less 
efficient to inhibit DAB38g-(Gly4Ser)2-mIL-3 than DAB389-
mIL-3 (Table 1). These results suggest that the presence of a 
peptidic spacer between the diphtheria toxin part of the fusion 
toxin and its mIL-3 part favors the accessibility of the hor-
mone for its receptor, hence increasing the binding affinity of 
the fusion toxin. Such increase in affinity correlated with an 
increase in toxicity was demonstrated in case of DAB389-IL-2 
fusion toxin derivatives when the size of the peptidic spacer 
was comprised between 10 and 20 amino acid residues [14]. 
We anticipate that our toxins will be cytotoxic to murine 
pluripotent hematopoietic stem cells in vivo and we shall in-
vestigate the treatment conditions to allow the specific remov-
al of those cells prior to bone marrow grafting in mice. 
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